Table 1. Characteristics of studies included in meta-analysis
Study | Country | Study design | DR criteria | Patients evaluated for DR | Anti-TNF | Concomitant therapeutics | Time of DR assessment | Prior anti-TNF use | |
|---|---|---|---|---|---|---|---|---|---|
UC | CD | ||||||||
Sebkova 2012 | Czech Republic | Retro | CDAI <150, no mucosal ulcerations | – | 60 | IFX† or ADA‡ | IMM§ (not specified, used in 30/60) | 1 year | Yes (17/60) |
Vadan 2012 | Romania | Pro | CDAI <150, no mucosal ulcerations | – | 49* | IFX† | IMM§ (5/49) | 1 year | No |
Vadan 2013 | Romania | Pro | CDAI <150, no mucosal ulcerations | 49* | IFX† | IMM§ (5/49) | 6 months | No | |
De Vos 2013 | Belgium | Pro | Partial Mayo <3, endo Mayo 0 | 87 | – | IFX† | AZA¶ (60/87) | 1 year | No |
Molander 2013 | Finland | Retro | No clinical symptoms, SES-CD 0–2, endo Mayo 0–1 | 69 | 183 | IFX† or ADA‡ | AZA¶ (140/252), 6MP (23/252), MTX (22/252) | 2 year | Not specified |
Dai 2014 | China | Pro | CDAI <150, Mayo <2, SES-CD 0–3, endo Mayo 0 | 107 | 109 | IFX† | IMM§ (66/109 CD, 34/107 UC) | 1 year | Yes (17 CD, 3 UC) |
Echarri 2015 | Spain | Pro | HBI <5, SES-CD 0–2 | – | 64 | ADA‡ | AZA¶ (44/68), steroids (56/68) | 6 months, 1 year, 2 year | No |
Yu 2015 | China | Retro | CDAI <150, SES-CD 0–2 | – | 106 | IFX† | AZA¶ (49/106) | 8 weeks | No |
Magro 2016 | Portugal | Pro | Mayo 0–2, endo Mayo 0–1, Geboe’s score <4 | 20 | – | IFX† | AZA¶ (17/20) | 8 weeks, 6 month, 1 year | No |
Pineton de Chambrun 2016 | France | Retro | Clinical physician assessment, no ulcerations | – | 67 | IFX† | AZA¶ (26/67) | 2 year | No |
Prymak 2016 | Ukraine | Pro | CAI and UCEIS (not defined) | 51 | – | IFX† | Mesalamine + steroids (25/51) | 8 weeks | No |
Zhang 2016 | China | Pro | CDAI <150, no ulcerations | – | 22 | IFX† | None | 6 month, 1 year, 2 year | No |
Kaymak 2018 | Switzerland | Retro | HBI <5 or CDAI <150, Fcal <150 × 2 years, no ulcerations (endoscopic and histologically) | – | 109 | IFX† | Not specified; steroid refractory | 2 year | Yes (11/109 prior ADA) |
Kumar 2018 | UK | Retro | CR + ER (undefined) | 56 | – | Golimumab | IMM§ (36/56) | 1 year | Not specified |
Munoz-Villafranca 2018 | Spain | Pro | pMayo 0–2, endo Mayo 0–1 | 53 | – | ADA‡ | IMM§ (38/53) | 8 weeks, 1 year | No |